ABSTRACT
Diffuse large B-cell lymphoma (DLBCL) is a common, highly aggressive and heterogeneous hematologic malignancy in adults. Patients with DLBCL have substantially differences in molecular biological characteristics, clinical manifestations, and prognosis. Increasing evidence shows that the tumor microenvironment plays an important role in the occurrence and development of DLBCL. CD47, an integrin related protein, is overexpressed in DLBCL cells and plays a key role in immune escape of lymphoma. This work reviews the research progress of CD47 in DLBCL TME in terms of CD47-related signal pathway, CD47 role in DLBCL TME, and therapeutic strategies targeting CD47 in DLBCL TME.
ABSTRACT
Objective:To evaluate the efficacy and safety of deoxyribonucleotide in intervention with solid tumor. Methods:A exper-imental study and randomized clinical trial were conducted. Experimental study part: MTT assay and S-180 sarcoma method were launched to observe whether the deoxyribonucleotide would affect the tumor growth. Clinical study part:86 patients of lung cancer, gastric cancer, colorectal cancer, liver cancer were divided into control group(n=43) and treatment group (n=43). Both group were given routine therapy,and the treatment group were given deoxyribonucleotide at the same time. Bone marrow suppression and live function were assessed after chemotherapy. Results:Chemotherapy Clinical effect did not improved in Deoxyribonucleotide group (47. 5% vs 44. 9%, P>0. 05), however, theⅢ-Ⅳbone,NKcellswere improved by deoxyribonucleotide (P<0. 05). What is more, the live injury of treat-ment group were less than the control group. Conclusion:Deoxyribonucleotide can decrese the occurace rate of live injury and bone mar-row suppression.